U.S. Electric Utilities Stock News

If you are wondering whether L3Harris Technologies is still worth buying after such a strong run, or if the upside has already been priced in, you are not alone. This is exactly what we are going to unpack here. The stock is up 36.4% year to date and 32.0% over the last year, even after a recent 2.3% dip over the past month that followed a 2.0% gain in the last week. Investors have been reacting to a steady drumbeat of defense contract wins and heightened geopolitical tensions, both of which...

Wondering if Comfort Systems USA is still worth buying after that massive run up in price, or if most of the upside is already baked in? This breakdown will help you evaluate whether the stock still offers value or is leaning into hype. The share price has pulled back around 1.5% over the last week, but it is still up 6.5% over the past month, 126.0% year to date, and an eye catching 1,748.4% over 5 years. This trajectory naturally raises questions about how much future growth is already...

American Water Works Company, Inc. recently declared a quarterly cash dividend of US$0.8275 per share, payable on March 3, 2026, to shareholders of record as of February 10, 2026. Alongside this, the company highlighted plans to invest over US$46.00 billion in water infrastructure over the next decade, responding to the American Society of Civil Engineers’ poor grades for West Virginia’s drinking water and wastewater systems. We’ll now explore how American Water’s very large decade-long...

Adobe recently reported its fiscal 2025 results, with revenue rising to US$23.77 billion and net income to US$7.13 billion, alongside issuing upbeat fiscal 2026 guidance and completing a large share repurchase program. The company also launched Photoshop, Express and Acrobat as integrated ChatGPT apps and highlighted accelerating AI adoption across Firefly and its broader creative and productivity suite, underscoring how generative AI is becoming central to Adobe’s product usage and...

If you are wondering whether Take Two Interactive Software is still worth buying after its huge run, you are not alone. This article is going to unpack what the current share price is really implying. The stock now trades around $244.53, drifting 1.7% lower over the last week but still up 4.0% over the past month and 33.6% year to date, with a 149.2% gain over three years shaping how investors see its potential and risk. Recent price moves have come alongside growing optimism around Take...

If you have been wondering whether Flowers Foods is starting to look like a bargain or a value trap, you are not alone. This breakdown will give you the context you need before making a move. Despite a rough longer term stretch, with the stock down 43.6% over the last year and 46.4% year to date, the recent 4.1% gain over the past week after a 3.2% dip in the last month hints that sentiment may be trying to find a floor. Recent coverage has focused on Flowers Foods as a defensive consumer...

Constellation Energy (CEG) has quietly been rewarding patient shareholders, with the stock up about 51% year to date and roughly 57% over the past year, handily beating the broader utilities space. See our latest analysis for Constellation Energy. That strength has not come out of nowhere, with a steady 30 day share price return of about 8 percent and a three year total shareholder return of roughly 328 percent pointing to investors repricing Constellation as a higher growth, lower risk...

American Electric Power Company (AEP) has been drifting lower over the past month even as its year to date return stays comfortably positive, a setup that often makes utilities investors recheck the fundamentals. See our latest analysis for American Electric Power Company. That recent 5.55% one month share price pullback to about $114.57 looks more like a pause within a strong year to date share price return of 24.61%, backed by a nearly 29% one year total shareholder return that suggests...

Criteo (CRTO) has quietly slid about 47% this year, even as its underlying ad tech business remains cash generative. That disconnect is prompting some investors to revisit the stock’s risk reward tradeoff. See our latest analysis for Criteo. Despite a steep year to date share price return of negative 46.9 percent, recent trading has steadied, with modest positive 1 day and 7 day share price returns hinting that heavy selling pressure may be easing while long term total shareholder returns...

Wondering if Cooper Companies is quietly turning into a value opportunity after a rough patch? This article will walk you through what the numbers are really saying about the stock. After sliding earlier this year, the share price has bounced about 3.2% in the last week and 12.4% over the last month, even though it is still down 10.6% year to date and 14.2% over the past year. That rebound has come as investors refocus on Cooper's positioning in specialty contact lenses and women's health,...

Wondering if JBS at around $14.34 is quietly trading below what it is really worth? You are not alone, and this breakdown is designed to help you decide if the stock deserves a spot on your watchlist. Over the last week JBS is up 3.5%, building on an 8.1% gain over the past month and a 3.4% rise year to date. These moves hint that investors are starting to reassess the company’s risk and growth profile. Recent headlines have focused on JBS’s ongoing push to streamline operations and invest...

If you are wondering whether Biogen is a quietly mispriced opportunity or a value trap in disguise, this breakdown walks through what the numbers are really saying about the stock. Biogen's share price has been choppy, down 2.5% over the last week but still up 2.4% over the past month and 14.3% year to date. This pattern hints at shifting market sentiment after years of lackluster longer term returns. Recent headlines around Biogen have focused on its push into new neurological treatments...

Wondering if Insight Enterprises is a beaten down opportunity or a value trap at today’s price? You are not the only one asking whether the current share price really reflects its underlying business. The stock has slid to around $79.62, with returns of about -6.3% over the last week, -11.6% over the last month, and a much steeper -46.7% year to date and -48.9% over the past year. This has reshaped how the market is pricing its future. Much of this shift has come as investors reassess IT...

If you are wondering whether Dropbox is quietly turning into a value opportunity while many investors focus on flashier tech names, this breakdown is for you. The stock is down 2.8% over the last week, 5.8% over the last month, and 3.3% year to date, but it is still up 27.7% over three years and 15.0% over five years, which tells a very different longer term story. Recent headlines have focused on Dropbox sharpening its product focus and pushing harder into AI driven features and workflow...

If you have been wondering whether Corcept Therapeutics is still worth buying after its big run, you are not alone; this stock has quietly turned into one of the more intriguing valuation stories in biotech. The share price now sits around $81.12, with a 7.4% gain over the last month, a hefty 62.3% year to date, and a 295.3% return over three years that has clearly shifted how the market prices its future. Recent headlines have focused on Corcept's expanding clinical pipeline and regulatory...

Gaming and Leisure Properties, Inc. recently appointed Michael Borofsky as a new independent director, expanding its board to eight members, seven of whom meet Nasdaq independence standards. Borofsky’s background in capital allocation, gaming investments, and complex transactions could influence how Gaming and Leisure Properties evaluates future deals, risk, and long-term capital deployment. Next, we’ll examine how adding Borofsky’s private equity and gaming experience to the board may...

AllianceBernstein Holding (AB) has been quietly grinding higher, with the stock up about 4% over the past 3 months and roughly 23% over the past year, outpacing many traditional asset managers. See our latest analysis for AllianceBernstein Holding. With the share price now around $39.85 and a 30 day share price return of 1.30 percent, the steadier 1 year total shareholder return of 22.82 percent suggests momentum is still building rather than fading. If you are weighing up where else...

In December 2025, Teva Pharmaceutical Industries obtained lender consent to extend the maturity of its senior unsecured sustainability-linked revolving credit facility from April 29, 2027, to April 29, 2028, while resetting key leverage and interest-cover covenants tied to potential Investment Grade Status. This covenant flexibility, together with recent progress in higher-margin branded and biosimilar products, gives Teva more room to align its balance sheet with its ongoing business...

Par Pacific Holdings (PARR) has been on a wild ride lately, slipping over the past week and month but still showing strong gains this year. This naturally raises questions about what is really driving the stock. See our latest analysis for Par Pacific Holdings. After such a strong run, with the share price now at $38.95 and a year to date share price return above 130 percent, the recent pullback looks more like momentum cooling than a complete change in the long term story. This is especially...

Wondering if Crown Holdings at around $101.53 is still a smart buy or if most of the upside has already been priced in? Here is a closer look at what the current share price really implies about its value. The stock has climbed 7.8% over the last week, 4.5% over the past month, and is up 25.0% year to date, adding to a 20.2% gain over the last year that has many investors taking a fresh look. Some of this momentum reflects renewed interest in packaging names as investors rotate toward...

Penske Automotive Group (PAG) has quietly added to recent gains, with the stock up about 6% over the past month even as its performance over the past 3 months remains slightly negative. See our latest analysis for Penske Automotive Group. Zooming out, Penske’s roughly 12% year to date share price return and strong multi year total shareholder returns suggest momentum has cooled recently, but the longer term trend still reflects solid value creation as investors reassess growth and cyclicality...

In the past quarter, Collegium Pharmaceutical reported a strong Q3, with revenue rising 31.4% year on year and topping analyst expectations by 10.7%, driven by its differentiated pain management medicines. The company also exceeded its full-year revenue guidance, signaling operational strength that reinforces its focus on specialty products for chronic pain. With Q3 revenue surpassing expectations by 10.7%, we’ll now examine how this performance influences Collegium’s existing investment...

Wondering if Exxon Mobil is still a buy after its huge run over the last few years, or if the easy money has already been made? You are not alone. Despite a 240.2% gain over 5 years and a solid 10.1% return over the last year, the stock has cooled recently, slipping 3.0% over the past week and 3.9% over the last month, while still up 6.9% year to date. Recent moves have been shaped by shifting expectations for long term oil and gas demand and renewed focus on energy security, as markets...

Wondering if Huntington Ingalls Industries is still a smart buy after its big run, or if the market has already priced in the upside? This breakdown will walk through what the current share price really implies. The stock has climbed to around $326.80, with gains of 3.8% over the last week, 4.1% over the last month, and 74.2% year to date, building on a 72.9% 1-year return and 123.6% over 5 years that has clearly shifted how investors see its prospects and risks. That re-rating has been...